Stevenson VL , Miller DH , Leary SM , et al.One year follow up study of primary and transitional progressive multiple sclerosis . J Neurol Neurosurg Psychiatry2000; 68: 713-718 .
2.
Cottrell DA , Kremenchutzky M , Rice GPA , et al.The natural history of multiple sclerosis: a geographically based study: 5. The clinical features and natural history of primary progressive multiple sclerosis . Brain1999; 122: 625-639 .
3.
McDonnell GV , Hawkins SA.Clinical study of primary progressive multiple sclerosis in Northern Ireland, UK . J Neurol Neurosurg Psychiatry1998; 64: 451-454 .
4.
Pericot I , Brieva L , Marzo ME , et al.Primary and transitional multiple sclerosis follow-up. Changes in clinical forms (Abstract) . Rev Neurol2000; 3: S223-S223 .
5.
Kremenchutzky OM , Cottrell D , Rice G , et al.The natural history of multiple sclerosis: a geographically based study: 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation . Brain1999; 122: 1941-1949 .
6.
Leary SM , Stevenson VL , Miller DH , Thompson, AJ.Problems in designing and recruiting to therapeutic trials in primary progressive multiple sclerosis . J Neurol1999; 246: 562-568 .
7.
Camp SJ , Stevenson VL , Thompson AJ , et al.Cognitive function in primary progressive and transitional progressive multiple sclerosis. A controlled study with MRI correlates . Brain1999; 122: 1341-1348 .
8.
McDonnell GV , Middleton D , Graham CA , et al.Primary progressive multiple sclerosis (MS) is associated with HLA-DR2 in Northern Ireland (Abstract) . Neurology1998; 50: A209-A210 .
9.
Neuhaus O , Hartung H-P.In search of a disease marker: the cytokine profile of primary progressive multiple sclerosis . Mult Scler2001; 7: 143-144 .
10.
Killestein J , Den Drijver BF , van der Graaff WL , et al.Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive disease . Mult Scler2001; 7: 145-150 .
11.
Durán I , Martínez-Cáceres EM , Brieva L , Tintoré M , Montalban X.Similar pro- and anti-inflammatory cytokine production in the different clinical forms of multiple sclerosis . Mult Scler2001; 7: 151-156 .
12.
Lucchinetti CF , Bruck W , Parisi J , et al.A quantitative analysis of oligodendrocytes in multiple sclerosis lesions: a study of 113 cases . Brain1999; 122: 2279-2295 .
13.
Revesz T , Kidd D , Thompson AJ , Barnard RO , McDonald WI.A comparison of the pathology of primary and secondary progressive multiple sclerosis . Brain1994; 117: 759-765 .
14.
Ingle GT , Stevenson VL , Miller DH , et al.Two year follow up study of primary and transitional progressive multiple sclerosis . Mult Scler2002; 8: 108-114 .
15.
Thompson AJ , Montalban X , Barkhof F , et al.Diagnostic criteria for primary progressive multiple sclerosis: a position paper . Ann Neurol2000; 47: 831-835 .
16.
McDonald WI , Compston A , Edan G , et al.Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis . Ann Neurol2001; 50: 121-127 .
17.
Leary SM , Stevenson VL , Miller DH , Thompson AJ.Problems in designing and recruiting to therapeutic trials in primary progressive multiple sclerosis . J Neurol1999; 246: 562-568 .
18.
Kremenchutzky M , Rice GPA , Hader W , Baskerville J , Ebers GC.The natural history of multiple sclerosis: a geographically based study: 6. Applications to planning and interpretation of clinical therapeutic trials in primary progressive multiple sclerosis . Brain1999; 122: 641-647 .
